MedTech Dive April 17, 2024
CEO Robert Ford highlighted new and upcoming products throughout the earnings call, calling the recently approved Triclip valve a “billion-dollar opportunity.”
Abbott CEO Robert Ford said Wednesday on an earnings call that a slate of recent approvals and a “highly productive” pipeline will accelerate growth.
The company recently received FDA authorization for a minimally invasive treatment for tricuspid regurgitation, a blood test to detect traumatic brain injury, and the ability to integrate its Freestyle Libre 2 Plus glucose sensor with Insulet’s Omnipod 5 insulin pump.
Abbott is looking to enter the competitive pulsed field ablation market with its Volt system. The company also plans to add new devices to its diabetes segment, including a dual-analyte sensor that can...
Today's Sponsors
Today's Sponsor